Traders Purchase Large Volume of Cypherpunk Technologies Put Options (NASDAQ:CYPH)

Key Points

• Put-option activity more than doubled: Investors purchased 4,236 CYPH put options, roughly 104% above the typical volume of 2,075, signaling heightened trading interest and potentially greater downside hedging.
• Analyst sentiment remains mixed: Cantor Fitzgerald maintained an “overweight” rating with a $1.60 price target, while other ratings ranged from “sell” to “hold.” The overall consensus is “Hold,” with a $1.60 target.
• The stock declined 3.7% to $2.19: CYPH traded on heavier-than-average volume, while a company director sold 20,000 shares at $1.72. Institutional investors own 30.46% of the company, and several firms recently initiated positions.

Cypherpunk Technologies (NASDAQ:CYPH - Get Free Report) was the recipient of unusually large options trading on Friday. Stock investors bought 4,236 put options on the stock. This is an increase of approximately 104% compared to the typical volume of 2,075 put options.

Analyst Upgrades and Downgrades

CYPH has been the topic of several research reports. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $1.60 price target on shares of Cypherpunk Technologies in a report on Thursday, August 27th. Weiss Ratings upgraded shares of Cypherpunk Technologies from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Monday, August 17th. Finally, Wall Street Zen raised shares of Cypherpunk Technologies from a "sell" rating to a "hold" rating in a research note on Saturday, July 4th. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus price target of $1.60.

Insider Buying and Selling

In other news, Director Thomas Dietz sold 20,000 shares of the stock in a transaction dated Wednesday, August 26th. The shares were sold at an average price of $1.72, for a total value of $34,400.00. Following the completion of the transaction, the director owned 132,500 shares of the company's stock, valued at approximately $227,900. This represents a 13.11% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 3.50% of the company's stock.

Hedge Funds Weigh In On Cypherpunk Technologies

Several large investors have recently modified their holdings of CYPH. Millennium Management LLC bought a new stake in shares of Cypherpunk Technologies in the fourth quarter worth $37,000. LPL Financial LLC bought a new position in Cypherpunk Technologies during the 4th quarter worth $38,000. Caitong International Asset Management Co. Ltd bought a new position in Cypherpunk Technologies during the 4th quarter worth $44,000. Sequoia Financial Advisors LLC acquired a new position in Cypherpunk Technologies during the 4th quarter worth about $56,000. Finally, HighTower Advisors LLC acquired a new position in Cypherpunk Technologies during the 4th quarter worth about $59,000. Institutional investors own 30.46% of the company's stock.

Cypherpunk Technologies Stock Down 3.7%

Shares of CYPH stock traded down $0.09 during mid-day trading on Friday, reaching $2.19. 5,265,259 shares of the stock traded hands, compared to its average volume of 3,954,247. The company has a market cap of $235.46 million, a price-to-earnings ratio of 3.90 and a beta of 0.33. The stock's fifty day simple moving average is $0.91 and its two-hundred day simple moving average is $0.86. Cypherpunk Technologies has a 1-year low of $0.27 and a 1-year high of $3.70.

Cypherpunk Technologies (NASDAQ:CYPH - Get Free Report) last released its quarterly earnings data on Wednesday, August 12th. The company reported $0.18 earnings per share (EPS) for the quarter.

About Cypherpunk Technologies

Cypherpunk Technologies Inc, previously known as Leap Therapeutics, Inc, is a company developing novel therapies for patients with cancer and implementing a digital asset treasury strategy focused on Zcash. The company’s research platform centers on modulating the tumor microenvironment to enhance anti-tumor immune responses. Cypherpunk’s proprietary pipeline includes DKN-01, a monoclonal antibody designed to neutralize Dickkopf-1 (DKK1), a protein implicated in tumor growth and immune evasion.

DKN-01 is being evaluated both as a monotherapy and in combination with checkpoint inhibitors such as pembrolizumab across multiple solid tumor indications, including gastroesophageal, pancreatic and other advanced malignancies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source